ImmunityBio, Inc. IBRX Proceeds From Related Party Debt
Proceeds From Related Party Debt at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromRelatedPartyDebt.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s proceeds from related party debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s proceeds from related party debt?
- ImmunityBio, Inc. (IBRX) reported proceeds from related party debt of $102.23M in Q1 2026.
- What is the long-term trend for ImmunityBio, Inc.'s proceeds from related party debt?
- Over 2 years (2022 to 2024), ImmunityBio, Inc.'s proceeds from related party debt has grown at a -100.0% compound annual growth rate (CAGR), from $174.13M to $0.
- What does proceeds from related party debt mean?
- Cash inflows derived from borrowing funds from entities or individuals with a pre-existing relationship to the company, such as major shareholders or executives. This often serves as a bridge financing mechanism when traditional capital markets are inaccessible.